Question · asked by 1 review
Hypertonic saline vs sodium‐2‐mercaptoethane sulphonate (Mistabron®): Pulmonary exacerbations
- Population
- adults and children with cystic fibrosis
- Intervention
- Hypertonic saline
- Comparison
- sodium‐2‐mercaptoethane sulphonate (Mistabron®)
- Outcome
- Pulmonary exacerbations
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Hypertonic saline vs sodium‐2‐mercaptoethane sulphonate (Mistabron®) Pulmonary exacerbations · adults and children with cystic fibrosis Nebulised hypertonic saline for cystic fibrosis (2023) · Cochrane Headline outcomes only | no estimate extracted | 1 study · 29 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Hypertonic saline vs amiloride · adults and children with cystic fibrosis · 1 review
- Hypertonic saline vs rhDNase with · adults and children with cystic fibrosis · 1 review
- Hypertonic saline vs mannitol · adults and children with cystic fibrosis · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.